Ginkgo Bioworks Holdings, Inc.

0001830214 FALSE 0001830214 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________ FORM 8-K ______________________________________________________________ CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 11, 2026 ______________________________________________________________ GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) ______________________________________________________________ Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 27 Drydock Avenue 8th Floor Boston , MA 02210 (Address of principal executive offices, including zip code) Registrant’s telephone number, including area code: ( 877 ) 422-5362 (Former name or former address, if changed since last report) ______________________________________________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act Title of each class Trading Symbol(s) Name of each exchange on which registered Class A common stock, par value $0.0001 per share DNA NYSE Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 5.07. Submission of Matters to a Vote of Security Holders. On June 11, 2026, Ginkgo Bioworks Holdings, Inc. (the “Company”) held its 2026 annual meeting of shareholders (the “Annual Meeting”). A total of 39,536,848 shares of Class A common stock and 8,405,525 shares of Class B common stock were present or represented by proxy at the Annual Meeting, representing approximately 77.15% of shares of Class A common stock and Class B common stock, entitled to vote as a single class at the Annual Meeting, and representing approximately 93.77% of shares of Class B common stock entitled to vote as a separate class at the Annual Meeting. Each holder of Class A common stock was entitled to one (1) vote for each share held on all matters voted upon by holders of Class A common stock. Each holder of Class B common stock was entitled to ten (10) votes for each share held on all matters voted upon. The shareholders voted on the matters presented at the Annual Meeting, and the shares present, in person or by proxy, were voted as follows: 1. Election of directors Proposal one was the election of six nominees to serve as directors of the Company, each until the next annual meeting of shareholders or until their successor shall have been elected and qualified. Holders of the Class B common stock, voting as a separate class, voted upon two nominees designated to be elected by the holders of Class B common stock. Holders of the Class A common stock and Class B common stock, voting together as a single class, voted upon four nominees designated to be elected by the holders of Class A common stock and Class B common stock. The results of the vote were as follows: Director nominees designated to be elected by holders of Class B common stock: Nominee Votes For Votes Against Abstentions Broker Non-Votes Jason Kelly 84,007,040 48,210 0 N/A Reshma Shetty 84,007,040 48,210 0 N/A Director nominees designated to be elected by holders of Class A and Class B common stock (voting together as a single class): Nominee Votes For Votes Against Abstentions Broker Non-Votes Ross Fubini 100,125,571 7,977,143 3,696,487 11,792,897 Christian Henry 94,211,345 13,927,076 3,660,780 11,792,897 Sri Kosuri 99,675,907 8,421,356 3,701,938 11,792,897 Harry E. Sloan 97,315,317 10,788,312 3,695,572 11,792,897 Pursuant to the foregoing votes, the six nominees listed above were elected to serve on the Company’s Board of Directors. There were no additional director nominations brought before the meeting. 2. Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm Proposal two was the ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, designated to be voted upon by the holders of Class A common stock and Class B common stock, voting together as a single class. The results of the vote were as follows: Votes For Votes Against Abstentions Broker Non-Votes 119,527,721 267,727 3,796,650 0 Pursuant to the foregoing vote, the ratification of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved. 3. Advisory vote to approve executive compensation Proposal three was an advisory vote to approve the compensation of the Company’s named executive officers, designated to be voted upon by the holders of Class A common stock and Class B common stock, voting together as a single class. The results of the vote were as follows: Votes For Votes Against Abstentions Broker Non-Votes 95,058,585 12,502,153 4,238,463 11,792,897 Pursuant to the foregoing vote, the compensation of the Company’s named executive officers was approved on an advisory basis. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GINKGO BIOWORKS HOLDINGS, INC. Date: June 12, 2026 By: /s/ Karen Tepichin Name: Karen Tepichin Title: General Counsel